Aeglea BioTherapeutics careers

Aeglea BioTherapeutics was founded in December 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin.

The convergence of discovery and technology has created a significant opportunity for Aeglea to potentially impact both the treatment of inborn errors of metabolism and cancer.

At Aeglea, we believe we can lead the industry in modulating the extremes of amino acid metabolism in both cancers and certain inborn errors of metabolism, with the hope of improved outcomes for patients.